)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
China Resources Boya Bio-pharmaceutical Group
China Resources Boya Bio-pharmaceutical Group (300294) investor relations material
China Resources Boya Bio-pharmaceutical Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M revenue fell 42.54% YoY to ¥846.9m; net profit attributable to shareholders fell 81.82% to ¥62.3m, reflecting market pressures and the change in consolidation after the Nanjing Xinbai disposal.
Strategy shifted further toward blood products, with Nanjing Xinbai’s 100% equity sale completed in June and a new plasma collection license secured in August.
Financial highlights
Q3 revenue was ¥203.4m, down 56.37% YoY; attributable net profit was ¥11.1m, down 90.52%, while adjusted net profit was ¥13.0m, down 70.72%.
9M attributable net profit was ¥62.3m, down 81.82%; adjusted net profit was ¥30.1m, down 85.64%, excluding non-recurring gains and losses.
9M operating profit was ¥11.8m versus ¥342.3m a year earlier; total revenue was ¥846.9m versus ¥1,473.9m.
Sales, management and R&D expenses declined 32.23%, 33.26% and 50.68% YoY, respectively, to ¥198.6m, ¥147.5m and ¥18.2m.
Segment performance
Following the Nanjing Xinbai sale, the business is focused on blood products; the divested subsidiary is no longer consolidated from June 2026.
Dalate Banner plasma station received a single-plasma collection license in August, supporting raw plasma supply capacity; the station’s losses increased and weighed on minority interests.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from China Resources Boya Bio-pharmaceutical Group
- Revenue and profit dropped significantly amid policy and market headwinds, with core focus on blood products.300294
H1 2026 - Q1 2026 saw steep declines in revenue and profit amid fierce competition and policy changes.300294Q1 2026
- Revenue up, profit down sharply; divestment and smart factory support core blood business.300294H2 2025
- Revenue and profit fell on divestitures, but blood products and plasma supply expanded.300294Q3 2024
- Revenue up, profit down YTD, cash flow pressured, Boya Xinhe deconsolidated.300294Q3 2025
- Revenue up 12.5% but net profit down 28.7% amid margin and policy pressures.300294H1 2025
- Revenue up 4.7% to RMB128.60b; net profit up 10.2%; major plasma acquisition, dividend declared.300294H1 2024
- Revenue up 19.49% but net profit down 8.25% as costs rise and cash flow turns negative.300294Q1 2025
- Net profit jumped 67% to ¥397M as core blood products outperformed despite revenue decline.300294H2 2024
Next China Resources Boya Bio-pharmaceutical Group earnings date
H2 202619 Mar, 2027
China Resources Boya Bio-pharmaceutical Group
Next China Resources Boya Bio-pharmaceutical Group earnings date
H2 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
China Resources Boya Bio-pharmaceutical Group Co., Ltd. is a biotechnology company specializing in the research, development, manufacturing, and distribution of plasma-derived biopharmaceutical products. The company's offerings include a range of products for immune system support, blood coagulation, and other therapeutic uses. China Resources Boya operates production facilities and leverages advanced bioprocessing technologies to ensure high standards in the manufacturing and quality control of its products. In addition to its focus on healthcare needs, the company also engages in initiatives aimed at expanding its biopharmaceutical pipeline. China Resources Boya Bio-pharmaceutical Group is headquartered in Chengdu, China, and its shares are listed on the Shenzhen Stock Exchange.